Molecular diagnostics and targeted therapies in non-small cell lung cancer (NSCLC): an update.

In this report, we discuss some of these updates. PMID: 31095926 [PubMed - in process]
Source: Discovery Medicine - Category: Research Tags: Discov Med Source Type: research

Related Links:

In this study, we presented the characteristics of the salivary microbiota in patients from NSCLC and healthy controls by sequencing of the 16S rRNA microbial genes. Our result revealed distinct salivary microbiota composition in patients from NSCLC compared to the healthy controls. As principal co-ordinates analysis (PCoA) showed, saliva samples clearly differed between the two groups, considering the weighted (p = 0.001, R2 = 0.17), and unweighted (p = 0.001, R2 = 0.25) UniFrac distance. Phylum Firmicutes (31.69% vs 24.25%, p
Source: Journal of Cancer - Category: Cancer & Oncology Authors: Tags: Research Paper Source Type: research
Conclusion. To date, there has been neither an effective way to detect if a patient is at high risk for autoimmune diabetes nor to prevent the complications associated with it. Regular glucose monitoring is the best method of early diabetes detection. In patients with new onset diabetes following treatment with ICIs, C-peptide levels and GADA should be screened, and insulin therapy should be prescribed to prevent hyperglycemic emergency while waiting for definite diagnosis.
Source: Frontiers in Endocrinology - Category: Endocrinology Source Type: research
Condition:   NonSmall Cell Lung Cancer Intervention:   Drug: DZD9008 Sponsor:   Dizal (Jiangsu) Pharmaceutical Co., Ltd. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: In conclusion,F-MPG or H-MPGhave good drug-like properties, better anti-tumor activity, andless liver damage after PEGylated compared with PD153035 which providing solid evidence for future clinical trials. The betterantitumor activityof F-MPG or H-MPGin vitroand in vivomay be related to the extended structure-activity. On the one hand, the modified drugs with lower lipophilicity and better water solubility reduced the clearance by hepatobiliary metabolism and improved the targeting with tumor. On the other hand, it may be related to self-assembly to nanoparticles after structure modified, while the EPR effect...
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational (Basic Science) Posters Source Type: research
278Objectives: To demonstrate that ultrasmall (sub 8-nm), multimodal (PET/optical), renal-clearable silica nanoparticles (Cornell prime dots or C’ dots) are an ideal drug delivery vehicle for enhanced delivery, efficacy, and improved therapeutic index of gefitinib, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in murine xenograft models of non-small cell lung cancer. Methods: Ultrasmall C’ dot nanoparticles (
Source: Journal of Nuclear Medicine - Category: Nuclear Medicine Authors: Tags: Oncology, Basic and Translational (Basic Science) II Source Type: research
In this study, we established and validated a method for determining gefitinib and its main metabolites, M605211, M387783, M537194 and M523595 in patients with non-small cell lung cancer (NSCLC) by liquid chromatography–tandem mass spectrometry (LC–MS/MS) method. The mobile phase was water: acetonitrile (35:65, v/v) with 0.1% formic acid at a flow‐rate of 0.35 mL/min, within a 3 min run time. Gefitinib and its main metabolites were separated on a X-Terra RP18 column (50 × 2.1 mm, 3.5 μm) at 40 ℃ and subjected to mass analysis using positive electro-spray io...
Source: Journal of Pharmaceutical and Biomedical Analysis - Category: Drugs & Pharmacology Source Type: research
This study evaluated clinical outcomes of afatinib in real-world practice. Medical records of patients who received afatinib for advanced EGFR-mutant NSCLC were retrospectively reviewed. In total, 128 patients were analyzed. Seventy-six patients received afatinib as the first-line setting and 52 as the re-challenge setting (i.e., after failure of prior first-generation TKI). There was no difference in patient characteristics, such as age, sex, and PS, between the first-line and the re-challenge settings. In the first-line setting, the median progression-free survival (PFS) was 17.8 months (95% confidence interval [CI]...
Source: Medical Oncology - Category: Cancer & Oncology Source Type: research
Authors: Zhao L, Wang J, Li H, Che J, Ma N, Cao B Abstract Ethnopharmacological Relevance: As an important Chinese herb injection, Tianfoshen (TFS) oral liquid is widely used in Chinese non-small cell lung cancer (NSCLC) patients. Aim of the Study: To evaluate the efficacy and safety of Tianfoshen (TFS) oral liquid plus chemotherapy in Chinese NSCLC patients with Qi and Yin deficiency syndrome, an observational study was conducted in Beijing Friendship Hospital between August 2012 and July 2016. Patients, enrolled in this study, were diagnosed with NSCLC and were treated with Cisplatin in combination with Pacli...
Source: Evidence-based Complementary and Alternative Medicine - Category: Complementary Medicine Tags: Evid Based Complement Alternat Med Source Type: research
Authors: Nagano T, Tachihara M, Nishimura Y Abstract Dacomitinib (PF-00299804, Vizimpro) was developed as a second-generation, oral, irreversible inhibitor of human epidermal growth factor receptor (EGFR)- 1, -2 and -4 tyrosine kinase. On September 27, 2018, the United States Food and Drug Administration (FDA) approved dacomitinib for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 L858R substitution mutations. On January 8, 2019, the Ministry of Health, Labour and Welfare of Japan approved this second-generation EGFR tyrosine kinase inhi...
Source: Drugs of Today - Category: Drugs & Pharmacology Tags: Drugs Today (Barc) Source Type: research
More News: Cancer | Cancer & Oncology | Conferences | Genetics | Lung Cancer | Non-Small Cell Lung Cancer | Oral Cancer | Research | Study